Rivaroxaban Indications (RIVAROXABAN)
Rivaroxaban is indicated for multiple thromboembolic and cardiovascular indications as specified in the FDA-approved prescribing information. [1]
Nonvalvular atrial fibrillation
Rivaroxaban is indicated to reduce the risk of stroke and systemic embolism in nonvalvular atrial fibrillation. [1]
Venous thromboembolism treatment
Rivaroxaban is indicated for treatment of deep vein thrombosis (DVT). [1]
Rivaroxaban is indicated for treatment of pulmonary embolism (PE). [1]
Risk reduction after DVT/PE
Rivaroxaban is indicated for reduction in the risk of recurrence of DVT or PE. [1]
VTE prophylaxis after orthopedic surgery
Rivaroxaban is indicated for prophylaxis of DVT, which may lead to PE, in patients undergoing knee or hip replacement surgery. [1]
VTE prophylaxis in acutely ill medical patients
Rivaroxaban is indicated for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding. [1]
Cardiovascular event risk reduction
Rivaroxaban is indicated to reduce risk of major cardiovascular events in patients with coronary artery disease (CAD). [1]
Rivaroxaban is indicated to reduce risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD. [1]
Pediatric thrombosis indications
Rivaroxaban is indicated for treatment of VTE and reduction in risk of recurrent VTE in pediatric patients from birth to less than 18 years. [1]
Rivaroxaban is indicated for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure. [1]
Sources of approved product labeling
Rivaroxaban indications vary by the specific rivaroxaban product and formulation. [1]